Genentech, Inc.
South San Francisco, USA · 11 authors
Genentech, Inc. (South San Francisco, USA): 11 authors and 6 papers in the de novo peptide sequencing catalog.
Departments
- Department of Antibody Engineering
- Department of Molecular Biology
- Department of Protein Chemistry
- Department of Proteomics & Biological Resources
Papers (6)
- The lysosomal endopeptidases Cathepsin D and L are selective and effective proteases for the middle‐down characterization of antibodies (2021, The FEBS Journal)
- De Novo MS/MS Sequencing of Native Human Antibodies (2017, Journal of Proteome Research)
- Resurrection of a clinical antibody: Template proteogenomic de novo proteomic sequencing and reverse engineering of an anti‐lymphotoxin‐α antibody (2011, PROTEOMICS)
- Template Proteogenomics: Sequencing Whole Proteins Using an Imperfect Database (2010, Molecular & Cellular Proteomics)
- Automated de novo protein sequencing of monoclonal antibodies (2008, Nature Biotechnology)
- De novo proteomic sequencing of a monoclonal antibody raised against OX40 ligand (2006, Analytical Biochemistry)
Its patents citing catalogued ones (2)
- KR20250078915A Prediction of molecular structure and properties by machine learning (priority 2022-09-27) cites US11644470B2
- WO2022204566A1 Using neural networks to predict peptide immunogenicity (priority 2021-03-25) cites US20200243164A1
Patent families filed by this organisation that cite a patent family catalogued here, as Google Patents lists the citations.